Gaiero David's Insider Trades & SAST Disclosures
Gaiero David's most recent trade in Cyteir Therapeutics Inc was a trade of 4,746 Common Stock done at an average price of $1.7 . Disclosure was reported to the exchange on Feb. 29, 2024.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Gaiero David.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Cyteir Therapeutics Inc | David Gaiero | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.69 per share. | 29 Feb 2024 | 4,746 | 100,018 | - | 1.7 | 8,021 | Common Stock |
| Cyteir Therapeutics Inc | David Gaiero | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Feb 2024 | 4,746 | 85,425 | - | - | Stock Option (Right to Buy) | |
| Cyteir Therapeutics Inc | David Gaiero | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.68 per share. | 29 Feb 2024 | 3,239 | 95,272 | - | 1.7 | 5,442 | Common Stock |
| Cyteir Therapeutics Inc | David Gaiero | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Feb 2024 | 3,239 | 16,196 | - | - | Stock Option (Right to Buy) | |
| Cyteir Therapeutics Inc | David Gaiero | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.69 per share. | 29 Feb 2024 | 2,373 | 102,391 | - | 1.7 | 4,010 | Common Stock |
| Cyteir Therapeutics Inc | David Gaiero | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Feb 2024 | 2,373 | 83,052 | - | - | Stock Option (Right to Buy) | |
| Cyteir Therapeutics Inc | Gaiero David | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Dec 2023 | 2,373 | 90,171 | - | - | Stock Option (Right to Buy) | |
| Cyteir Therapeutics Inc | David Gaiero | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.69 per share. | 11 Dec 2023 | 2,373 | 92,033 | - | 1.7 | 4,010 | Common Stock |
| Cyteir Therapeutics Inc | David Gaiero | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Dec 2023 | 1,620 | 19,435 | - | - | Stock Option (Right to Buy) | |
| Cyteir Therapeutics Inc | Gaiero David | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.68 per share. | 11 Dec 2023 | 1,620 | 89,660 | - | 1.7 | 2,722 | Common Stock |
| Cyteir Therapeutics Inc | David Gaiero | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2023 | 113,900 | 113,900 | - | - | Stock Option (Right to Buy) | |
| Cyteir Therapeutics Inc | David Gaiero | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 1.49 per share. | 03 Feb 2023 | 5,000 | 9,100 | - | 1.5 | 7,450 | Common Stock |
| Cyteir Therapeutics Inc | David Gaiero | Vice President, Finance | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Feb 2022 | 23,000 | 23,000 | - | - | Stock Option (Right to Buy) | |
| Cyteir Therapeutics Inc | David Gaiero | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.68 per share. | 20 Dec 2021 | 4,100 | 4,100 | - | 1.7 | 6,888 | Common Stock |
| Cyteir Therapeutics Inc | David Gaiero | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Dec 2021 | 4,100 | 73,639 | - | - | Stock Option (Right to Buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges